Sun, Dec 28, 2014, 4:46 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • epb2840 epb2840 Apr 4, 2014 10:19 AM Flag

    UBS today ...

    "Sovaldi scripts for the week ending March 28 were released this morning with total scripts of 7,434, up 4% from last week. New Rx were 3,878, up 4% w/w. This is the last full-week data in 1Q, and there will be one more day's scripts left this month.

    A total of 58,865 scripts and 37,636 new scripts have been recorded in 1Q through March 28. These numbers show that 1Q revenues would beat current 1Q Sovaldi consensus (Bloomberg) of $705m.

    The math implies that conservatively, we are tracking to $2.5b already:
    - Assume 95% complete therapy (97.5% refill in months 2 and 3 each)
    - Assume 12% gross-to-net pricing (more conservative than Gilead comments imply)
    - Apply the 0.88 correction factor suggested by 4Q scripts vs. reported demand
    - Assume 10% of NRx are actually refills "

    Q1 Sovaldi rev of 2.5B v. consensus of 700M ... A 2 BILLION BEAT, FOR GOODNESS SAKES ... do the math - 37,600 x say, $70,000 per throw (and we're not including the UK, Germany, France, Austria, Sweden etc.)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
93.79+2.50(+2.74%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.